MK-6325

DB15249InvestigationalSmall molecule

MK-6325 is under investigation in clinical trial NCT01329913 (Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)).

Formula / weight: C₄₂H₅₆N₆O₉S · 821.0 g/mol (avg)
Code names: MK-6325

Resolves to

Compound

UNII59LD48P07KCAS1263814-52-3

Structure

InChIKeyBLFKRFGLQFYXDF-WAZRELCSSA-NSMILES

COC1=CC2=C(C=C1)N=C1CCCCC[C@@H]3CCC[C@H]3OC(=O)N[C@H]3CCCCC\C=C\[C@@H]4C[C@]4(NC(=O)[C@@H]4C[C@H](CN4C3=O)OC1=N2)C(=O)NS(=O)(=O)C1(C)CC1

Targets

P26664Genome polyprotein

What you can answer from here — as of April 02, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with MK-6325, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account